Biocon's Q4 FY 2025-26 Quarterly Results

Result Summary

• Biocon Ltd reported a 6.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.6%.
• Its expenses for the quarter were up by 4.3% QoQ and 6.4% YoY.
• The net profit decreased 483.4% QoQ and decreased 56.8% YoY.
• The earnings per share (EPS) of Biocon Ltd stood at 0.79 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Biocon Ltd is a leading biopharmaceutical company based in India, known for its significant contributions to the healthcare industry. The company primarily engages in the development and manufacture of generic active pharmaceutical ingredients (APIs), biosimilar medicines, and novel biologics. Biocon operates in the highly competitive biotechnology sector, focusing on affordable healthcare solutions. The company has a global presence with a diversified portfolio that includes products in areas such as diabetes, oncology, and autoimmune diseases. In recent times, Biocon has been actively enhancing its research and development capabilities and expanding its manufacturing infrastructure.

Revenue

During the fourth quarter of fiscal year 2026 (Q4FY26), Biocon Ltd reported a total income of ₹4569.10 crores. This reflects a quarter-over-quarter (QoQ) increase of 6.5% compared to ₹4290.30 crores in Q3FY26. On a year-over-year (YoY) basis, there was a 2.6% rise from the ₹4453.90 crores recorded in Q4FY25. This upward trend in total income suggests an improvement in revenue generation for the company during this period.

Profitability

Biocon Ltd's profitability metrics for Q4FY26 illustrate a mixed performance. The company recorded a profit before tax (PBT) of ₹247.50 crores, which signifies a turnaround from a loss of ₹67.80 crores in the previous quarter (Q3FY26). However, when compared to the same quarter in the previous year (Q4FY25), where the PBT was ₹486.80 crores, there is a noticeable decline of 49.2% YoY. The profit after tax (PAT) for Q4FY26 stands at ₹198.60 crores, again showing recovery from a loss of ₹51.80 crores in Q3FY26, but a significant decline of 56.8% YoY from ₹459.40 crores in Q4FY25. Earnings per share (EPS) for Q4FY26 are ₹0.79, down from ₹2.87 in Q4FY25, marking a YoY decline of 72.5%.

Operating Metrics

The total expenses for Biocon Ltd in Q4FY26 were ₹4241.20 crores, representing a 4.3% increase QoQ from ₹4064.70 crores in Q3FY26. On a YoY basis, total expenses rose by 6.4% from ₹3987.50 crores in Q4FY25. The tax expense for the quarter stood at ₹48.90 crores, contrasting with a tax credit of ₹16.00 crores in Q3FY26. This marks a YoY increase of 78.5% from ₹27.40 crores in Q4FY25. These metrics indicate changes in the company’s cost structure and tax obligations over the observed periods.